The role of asymmetric dimethylarginine and arginine in the failing heart and its vasculature (Q37798082)

23 August 2017

title

The role of asymmetric dimethylarginine and arginine in the failing heart and its vasculature (English)

1 reference

23 August 2017

7

Bas A J M de Mol

1 reference

23 August 2017

Marlieke Visser

1

1 reference

23 August 2017

Walter J Paulus

2

1 reference

23 August 2017

Mechteld A R Vermeulen

3

1 reference

23 August 2017

Milan C Richir

4

1 reference

23 August 2017

Mariska Davids

5

1 reference

23 August 2017

Willem Wisselink

6

1 reference

23 August 2017

Paul A M van Leeuwen

8

1 reference

23 August 2017

publication date

5 October 2010

1 reference

European Journal of Heart Failure

23 August 2017

published in

1 reference

23 August 2017

volume

12

1 reference

23 August 2017

issue

12

1 reference

23 August 2017

page(s)

1274-1281

1 reference

Nitric oxide and nitric oxide synthase isoforms in the normal, hypertrophic, and failing heart

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ158

The clinical significance of asymmetric dimethylarginine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ158

The L-arginine paradox: Importance of the L-arginine/asymmetrical dimethylarginine ratio

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ158

Asymmetrical dimethylarginine (ADMA) in critically ill patients: high plasma ADMA concentration is an independent risk factor of ICU mortality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ158

Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ158

Low arginine/asymmetric dimethylarginine ratio deteriorates systemic hemodynamics and organ blood flow in a rat model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ158

LINCS: L-NAME (a NO synthase inhibitor) in the treatment of refractory cardiogenic shock: a prospective randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ158

Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ158

ADMA and oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ158

Role of oxidative stress in cardiac hypertrophy and remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ158

Dimethylarginine dimethylaminohydrolase and endothelial dysfunction in failing hearts

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ158

L-arginine transporters in cardiovascular disease: a novel therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ158

Abnormalities in L-arginine transport and nitric oxide biosynthesis in chronic renal and heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ158

Relations between plasma asymmetric dimethylarginine (ADMA) and risk factors for coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ158

Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ158

Variance of DDAH/PRMT/ADMA pathway in atrial fibrillation dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ158

Immunolocalisation and activity of DDAH I and II in the heart and modification post-myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ158

Dimethylarginine dimethylaminohydrolase activity modulates ADMA levels, VEGF expression, and cell phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ158

Nebivolol reduces asymmetric dimethylarginine in endothelial cells by increasing dimethylarginine dimethylaminohydrolase 2 (DDAH2) expression and activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ158

all-trans-Retinoic acid increases nitric oxide synthesis by endothelial cells: a role for the induction of dimethylarginine dimethylaminohydrolase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ158

Recent advances in arginine metabolism: roles and regulation of the arginases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ158

L-arginine protects human heart cells from low-volume anoxia and reoxygenation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ158

The vascular effects of L-Arginine in humans. The role of endogenous insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ158

Myocardial contractile effects of L-arginine in the human allograft.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ158

L-arginine fails to prevent ventricular remodeling and heart failure in the spontaneously hypertensive rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ158

L-arginine therapy in acute myocardial infarction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ158

Sepsis: an arginine deficiency state?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ158

Therapeutic use of citrulline in cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ158

Pharmacokinetic and pharmacodynamic properties of oral L-citrulline and L-arginine: impact on nitric oxide metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ158

Regulation of nitric oxide synthesis by dietary factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ158

Specific amino acids in the critically ill patient--exogenous glutamine/arginine: a common denominator?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ158

Effect of nitric oxide synthase inhibition on haemodynamics and outcome of patients with persistent cardiogenic shock complicating acute myocardial infarction: a phase II dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFQ158

21 January 2018

Identifiers

DOI

10.1093/EURJHF/HFQ158

1 reference

release_hb7th7zqeva6fne2x5wocnyvde

23 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/hb7th7zqeva6fne2x5wocnyvde

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference